GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OKYO Pharma Ltd (NAS:OKYO) » Definitions » EPS (Diluted)

OKYO Pharma (OKYO Pharma) EPS (Diluted) : $-0.16 (TTM As of Mar. 2023)


View and export this data going back to 2022. Start your Free Trial

What is OKYO Pharma EPS (Diluted)?

OKYO Pharma's Earnings per Share (Diluted) for the six months ended in Mar. 2023 was $-0.16. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.16.

OKYO Pharma's EPS (Basic) for the six months ended in Mar. 2023 was $-0.16. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.16.

OKYO Pharma's EPS without NRI for the six months ended in Mar. 2023 was $-0.16. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.16.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


OKYO Pharma EPS (Diluted) Historical Data

The historical data trend for OKYO Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OKYO Pharma EPS (Diluted) Chart

OKYO Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 - -0.32 -0.36 -0.61

OKYO Pharma Semi-Annual Data
Sep13 Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 - -0.14 - -0.16

Competitive Comparison of OKYO Pharma's EPS (Diluted)

For the Biotechnology subindustry, OKYO Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OKYO Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OKYO Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where OKYO Pharma's PE Ratio falls into.



OKYO Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

OKYO Pharma's Diluted EPS for the fiscal year that ended in Mar. 2023 is calculated as

Diluted EPS (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-13.272-0)/22.257
=-0.60

OKYO Pharma's Diluted EPS for the quarter that ended in Mar. 2023 is calculated as

Diluted EPS (Q: Mar. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-8.185-0)/51.040
=-0.16

EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OKYO Pharma  (NAS:OKYO) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


OKYO Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of OKYO Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


OKYO Pharma (OKYO Pharma) Business Description

Traded in Other Exchanges
Address
14/15 Conduit St, Floor 4, London, GBR, W1S 2XJ
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions on various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
Executives
John P Brancaccio director C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob director, officer: Chief Executive Officer
Gabriele M Cerrone director, 10 percent owner, officer: Executive Chairman 265 EAST 66TH STREET, SUITE 16G, NEW YORK NY 10021
Bernard Denoyer director C/O CALLISTO PHARMACEUTICALS, INC., 420 LEXINGTON AVENUE, SUITE 1609, NEW YORK NY 10170
Willy Jules Simon director PLAYLOGIC INTERNATIONAL NV, CONCERTGEBOUWPLEIN 13, AMSTERDAM P7 1071 LL
Keeren Shah officer: Chief Financial Officer 55 PARK LANE, LONDON X0 W1K 1NA